Analystreport

Royalty Pharma plc (NASDAQ: RPRX) had its "buy" rating re-affirmed by analysts at Citigroup Inc..

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations